Completed

ILUMIEN IOptimizing Stent Parameters with Optical Coherence Tomography (OCT) in Patients Undergoing Fractional Flow Reserve (FFR) and Percutaneous Coronary Intervention

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
Study Aim

This study aims to observe how often Optical Coherence Tomography (OCT) guidance is used during stenting procedures in patients undergoing Fractional Flow Reserve (FFR) and Percutaneous Coronary Intervention, and how this relates to patient outcomes both in-hospital and up to 12 months later.

What is being collected

Device Data

Collected from today forward - Prospective
Device
Who is being recruted

Amino Acid Metabolism, Inborn Errors+19

+ Arterial Occlusive Diseases

+ Arteriosclerosis

Over 18 Years
+22 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Case-Only

Examining characteristics of individuals with a disease in order to identify genetic or environmental factors contributing to the condition.
Observational
Study Start: December 2012
See protocol details

Summary

Principal SponsorAbbott Medical Devices
Last updated: July 2, 2020
Sourced from a government-validated database.Claim as a partner

Study start date: December 11, 2012

Actual date on which the first participant was enrolled.

Optical coherence tomography (OCT) is an imaging modality that uses near-infrared light to produce high resolution, real-time images that are clearer and more quickly produced than those produced by intravascular ultrasound (IVUS). OCT imaging is performed utilizing an imaging catheter with a single optical fiber core that both emits light and records its reflection while simultaneously rotating 360° during continuous pullback within the coronary artery. Fractional Flow Reserve (FFR) is a pressure-derived, lesion-specific, physiological index determining the hemodynamic severity of intracoronary lesions. FFR is measured by placing a pressure guidewire across the lesion of interest and pharmacologically inducing hyperemia. The ratio of distal to proximal pressure allows the physician to physiologically determine if the narrowing is the cause of ischemia. the goal of this study is to define new parameters for stent optimization, benefitting from the unique Fourier-domain (FD-OCT) capabilities. This stage I study will identify the parameters which will be prospectively tested in a second stage II protocol. In hospital, 30 day, and 12 month outcomes data will be correlated with OCT baseline findings in order to identify optimal stent implant parameters.

Principal SponsorAbbott Medical Devices
Last updated: July 2, 2020
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

418 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Case-only

These studies focus only on individuals who have a specific disease. Researchers examine patterns—often genetic or environmental—to uncover what might be linked to the condition.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 18 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Amino Acid Metabolism, Inborn ErrorsArterial Occlusive DiseasesArteriosclerosisBrain DiseasesBrain Diseases, MetabolicCardiovascular DiseasesCentral Nervous System DiseasesCoronary DiseaseHeart DiseasesMetabolic DiseasesMetabolism, Inborn ErrorsCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesNervous System DiseasesNutritional and Metabolic DiseasesVascular DiseasesMyocardial IschemiaBrain Diseases, Metabolic, InbornGenetic Diseases, InbornGenetic Diseases, X-LinkedUrea Cycle Disorders, InbornCoronary Artery DiseaseOrnithine Carbamoyltransferase Deficiency Disease

Criteria

7 inclusion criteria required to participate
Age >= 18 years

Angiographically significant ( > 50% visual estimation) stenosis present in at least one native coronary artery

De novo coronary artery disease in target vessel

Elective or ad hoc PCI, stable angina, acute coronary syndrome (unstable angina and NSTEMI)

Show More Criteria

15 exclusion criteria prevent from participating
Any condition that precludes the subject from undergoing PCI, for example subjects with heparin induced thrombocytopenia, or contrast allergy

Any other medical condition that in the opinion of the investigator will interfere with patient safety or study results

Aorto-ostial lesion location within 3 mm of the aorta junction (both right and left)

Currently participating in another clinical study that interferes with study results

Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

One single intervention group is designated in this study

This study does not include a placebo group 

Treatment Groups

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 36 locations

University Hospital - Univ. of Alabama at Birmingham (UAB)

Birmingham, United StatesOpen University Hospital - Univ. of Alabama at Birmingham (UAB) in Google Maps

Scripps Clinic, Green Hospital

La Jolla, United States

Florida Hospital Orlando

Orlando, United States

Emory University Hospital

Atlanta, United States
Completed36 Study Centers